At the core of ketamine’s proposed analgesic mechanism is its role as an NMDA receptor antagonist. These receptors, integral components of the central nervous system, are implicated in excitatory neurotransmission and play a pivotal role in the amplification of pain signals in chronic pain states. By blocking NMDA receptors, ketamine is hypothesized to disrupt the pathologic neural sensitization that underpins many chronic pain conditions. Despite the theoretical rationale and increasing clinical enthusiasm for ketamine’s utility, the new review delineates a conspicuous absence of robust, high-certainty evidence demonstrating clear clinical benefits.

The systematic review team, including experts from UNSW Sydney, Neuroscience Research Australia (NeuRA), and Brunel University of London, undertook a meticulous appraisal of randomized controlled trials involving ketamine as well as memantine, dextromethorphan, amantadine, and magnesium. The trials analyzed encompassed various dosing regimens and chronic pain etiologies, yet across this heterogeneous landscape, no consistent or compelling evidence emerged supporting ketamine’s efficacy in reducing long-term pain intensity or improving patient outcomes.

Crucially, the review highlights that the certainty of existing evidence remains low to very low, primarily due to inherent limitations such as small sample sizes, methodological inconsistencies, and high risks of bias. Such weak evidence underscores an urgent need for well-powered, rigorously designed clinical trials that can conclusively delineate therapeutic value. Without such data, clinicians are left to navigate a precarious balance between offering potentially ineffective treatment and exposing patients to substantial risks.

Concerns around adverse effects surfaced prominently within the review’s findings. Ketamine’s administration, particularly via intravenous routes, is associated with psychotomimetic side effects including delusions, paranoia, and delirium. These neuropsychiatric symptoms, though often transient, can be profoundly distressing and debilitating for patients, complicating treatment adherence and overall quality of life. Gastrointestinal adverse events such as nausea and vomiting were also frequently reported, further diminishing the drug’s tolerability in the chronic pain population.

The clinical dilemma is sharpened by the paradox that while ketamine may alleviate acute nociceptive pain, its translation into effective chronic pain management remains unproven and fraught with harm. The review authors caution that attempts to titrate doses to mitigate side effects may not reliably prevent these adverse outcomes, thus challenging the feasibility of safe long-term use. This is particularly pertinent given the vulnerable nature of patients with chronic pain, who often have coexisting psychological comorbidities.

Interestingly, the systematic review notes a glaring absence in current research regarding two critical dimensions frequently cited as secondary benefits of ketamine therapy: reduction in depressive symptoms and decreased opioid consumption. With depression and opioid tolerance common comorbidities in chronic pain syndromes, these factors form a significant axis upon which ketamine’s value proposition often rests. Yet the lack of empirical data leaves these purported benefits speculative and unsubstantiated within the evidence base.

Experts involved in the review emphasize the broader implications of these findings for clinical practice and policy. The pervasive use of ketamine and other NMDA antagonists in chronic pain treatment—often driven by clinician enthusiasm and patient desperation—risks repeating the pitfalls witnessed in opioid prescribing. The opioid epidemic, fueled in part by premature adoption of therapies without sufficient evidence, serves as a cautionary tale underscoring the necessity of judicious, evidence-aligned prescribing.

The authors advocate for heightened caution among clinicians, urging restraint in the widespread adoption of ketamine until definitive high-quality trials clarify its role. They assert that investment in such research is not merely academic but a pressing public health priority, with the potential to inform safer, more effective pain management paradigms. This call aligns with a growing consensus within pain medicine emphasizing personalized care grounded in empirical validation.

From the patient perspective, the review aims to empower informed decision-making conversations between clinicians and individuals living with chronic pain. By transparently communicating the uncertainties surrounding ketamine’s benefits and highlighting the risks, patients can better weigh potential outcomes within the context of their personal health goals and treatment tolerance thresholds.

In sum, this Cochrane systematic review delivers an important recalibration of ketamine’s therapeutic narrative in chronic pain management. It underscores a profound knowledge gap, one marked by ambiguity regarding efficacy and a clear signal of adverse effect risks. Until the scientific community addresses this through rigorously conducted, large-scale trials, ketamine’s place in chronic pain care must remain circumspect, guided foremost by prudence and patient safety.

The implications extend beyond ketamine alone, casting a reflective light on the broader category of NMDA receptor antagonists. Their theoretical allure notwithstanding, the current landscape illustrates the complexity of translating molecular pharmacology into clinical success in chronic pain—a field marked by heterogeneous pathophysiology and multidimensional patient experiences.

Ultimately, this review invites both clinicians and researchers to critically examine prevailing assumptions and to commit to evidence-driven innovation. It is a pivotal moment to recalibrate treatments based on science rather than enthusiasm and to safeguard the wellbeing of patients navigating the challenging terrain of chronic pain.

Subject of Research: People
Article Title: Ketamine and other NMDA receptor antagonists for chronic pain
News Publication Date: 18-Aug-2025
Web References: http://dx.doi.org/10.1002/14651858.CD015373.pub2
Keywords: Pain, Chronic pain, Fibromyalgia, Neuropathic pain, Clinical medicine, Medical treatments, Drug therapy, Medications, Analgesics, Pharmaceuticals, Illicit drugs

Postoperative pain management in pediatric patients presents unique challenges that are significantly amplified in children who have received chemotherapy before surgery. Chemotherapy is known not only to exert cytotoxic effects on cancerous cells but also to induce a myriad of neurological alterations, including peripheral and central sensitization mechanisms. Such sensitization often leads to heightened pain responses following surgical trauma, thereby complicating standard analgesic regimens. The investigation led by Zhou, Bian, Zhang, and colleagues delves into how S-ketamine might counteract this augmented pain sensitivity.

S-ketamine, the S(+) enantiomer of ketamine, has garnered attention for its robust analgesic properties and a more favorable side effect profile relative to racemic ketamine. Acting swiftly on NMDA receptors—which play a critical role in central sensitization and chronic pain development—S-ketamine interrupts the pathological excitatory glutamatergic signaling that underpins heightened pain states. The study’s focus on pediatric patients with a history of chemotherapy underscores the importance of tailored anesthesia that considers altered neurochemistry and immune responses post-chemotherapy.

The research employed a meticulous clinical trial framework involving children scheduled for surgery after undergoing chemotherapy regimens. Using standardized pain assessment tools and biochemical markers of nociceptive processing, the investigators assessed postoperative pain sensitivity and analgesic requirements. Intriguingly, children administered S-ketamine displayed a significant reduction in pain scores compared to controls, with fewer incidences of opioid-related adverse effects. This suggests that S-ketamine induces a multifaceted modulation of pain pathways, potentially reducing the reliance on opioids and their associated risks.

One of the pivotal aspects examined was the pharmacodynamic interaction between S-ketamine and chemotherapy-altered neural substrates. Chemotherapeutic agents can potentiate neuroinflammatory cascades, increase oxidative stress, and disrupt the balance of excitatory and inhibitory neurotransmission within the central nervous system. S-ketamine’s antagonism of NMDA receptors appears to recalibrate this disequilibrium, attenuating the amplification of nociceptive signals that typically manifest postoperatively. The study provides novel insights into this mechanistic interplay, substantiating S-ketamine as more than just a symptomatic analgesic but a modulator of underlying pathophysiology.

In addition to analgesia, the investigators noted secondary effects on mood and cognitive function—domains often impaired in pediatric oncology patients. By dampening glutamate-mediated excitotoxicity, S-ketamine may confer neuroprotective benefits during the perioperative period, although this warrants further longitudinal studies. This dual action introduces exciting implications for comprehensive perioperative care, wherein modulation of pain sensitivity is coupled with preservation of cognitive integrity.

From a clinical standpoint, the dosing regimen and administration protocols of S-ketamine were carefully optimized to balance efficacy and safety. The research navigated concerns surrounding psychomimetic side effects historically associated with ketamine, utilizing the S-enantiomer to minimize dysphoria and hallucinations. The study’s careful titration and monitoring ensured excellent tolerability, which is paramount when treating vulnerable young patients already burdened with the sequelae of chemotherapeutic exposure.

The significance of this research extends beyond the immediate clinical outcomes. It marks a critical step towards personalized medicine in pediatric anesthesiology, where factors such as prior chemotherapy, developmental neurobiology, and individual pain phenotypes inform therapeutic decisions. These findings encourage clinicians to rethink traditional analgesic paradigms and consider NMDA receptor antagonism as a cornerstone in multimodal pain management, particularly in complex cases complicated by oncological treatments.

Technological advancements in pain assessment also played a key role in the success of this investigation. The integration of quantitative sensory testing with molecular biomarkers allowed for a comprehensive profiling of pain sensitivity changes, offering objective endpoints that transcend subjective reports. This methodological rigor enhances the reproducibility and applicability of the findings across diverse clinical settings.

Importantly, the implications of this study transcend pediatric surgery. Neuropathic and sensitization-related pain conditions are notoriously refractory to conventional analgesics in multiple patient populations. By unraveling the mechanisms through which S-ketamine modulates pain post-chemotherapy, the research sheds light on potential translational applications in adult oncology, chronic pain syndromes, and possibly neurodegenerative disorders with pain components.

However, the authors prudently call for cautious optimism. While the reduction in postoperative pain sensitivity is promising, long-term safety data and effects on developmental neuroplasticity require extended follow-up. Additionally, larger multicenter trials are necessary to validate these findings and to optimize dosing algorithms for varied pediatric subpopulations. The intersection of pharmacology, neurobiology, and pediatric oncology remains a fertile ground for future exploration.

This study also highlights the evolving landscape of analgesic drug development. S-ketamine represents a shift towards drugs that target specific receptor systems involved in pain amplification rather than just suppressing pain symptoms. Such targeted therapies embody a paradigm shift, prioritizing the modification of disease pathways to achieve sustained relief and improved quality of life.

In conclusion, the investigation by Zhou and colleagues pioneers an innovative approach to managing postoperative pain sensitivity in children with preoperative chemotherapy. By demonstrating the clinical utility of S-ketamine as an effective and safe analgesic adjunct, the study not only advances pediatric pain medicine but also offers hope for millions of children undergoing cancer treatment worldwide. If integrated thoughtfully into clinical practice, S-ketamine may herald a new era of precision analgesia, mitigating suffering and improving outcomes in this delicate patient demographic.

As the medical community continues to grapple with the complexities of pediatric oncology and perioperative care, studies like this underscore the importance of cross-disciplinary collaboration and translational research. Harnessing the power of pharmacology, neuroscience, and clinical expertise, such endeavors promise to transform how we understand and treat pain—particularly in those whose lives are already burdened by formidable medical challenges.

The journey from bench to bedside for S-ketamine in this context encapsulates the spirit of modern scientific innovation: driven by unmet clinical needs, grounded in rigorous experimental methodology, and propelled by the aspiration to make tangible differences in patient care. This research stands as a testament to that mission and invites ongoing inquiry into the potentials of NMDA receptor modulation in pediatric pain management.

Subject of Research: Effect of S-ketamine on postoperative pain sensitivity in pediatric patients with preoperative chemotherapy

Article Title: Effect of S-ketamine on postoperative pain sensitivity in children with preoperative chemotherapy

Article References:
Zhou, S., Bian, Y., Zhang, K. et al. Effect of S-ketamine on postoperative pain sensitivity in children with preoperative chemotherapy. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04146-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-025-04146-2